BDM-2
Product Specifications
UNSPSC Description
BDM-2 is an IN-LEDGF allosteric inhibitor (INLAI) of HIV-1 integrase (IN refers to integrase) (IC50=47 nM) with potent anti-Retroviral (ARV) activity. BDM-2 shows IN multimerization activation effect with an AC50 value of 20 nM. BDM-2 blocks the interaction between the catalytic core domain of IN (IN-CCD) and the Integrase binding domain of LEDGF/p75 (IBD), with an IC50 value of 0.15 μM. BDM-2 exhibits highly selective and favorable cytotoxicity[1].
Target Antigen
HIV; HIV Integrase
Type
Reference compound
Related Pathways
Anti-infection;Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/bdm-2.html
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(C)(C)O[C@@H](C1=C(C2=CC=C(OCCC3)C3=C2)C(C4CC4)=CC=C1C)C(O)=O
Molecular Weight
394.50
References & Citations
[1]Le Rouzic E, et al. Biological and structural analysis of new potent Integrase-LEDGF allosteric HIV-1 inhibitors. bioRxiv, 2023: 2023.01. 28.523533.
Shipping Conditions
Blue Ice
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-153094/BDM-2-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-153094/BDM-2-SDS-MedChemExpress.pdf
Clinical Information
Phase 1
CAS Number
1643876-33-8
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6254455-01 0.1 mL
CD134 (CD134 Antigen, ACT35, ACT35 Antigen, Lymphoid Activation Antigen ACT35, OX40, OX40 Cell Surface Antigen, OX40 Homolog, OX40L Receptor, RP5-902P8.3, TAX Transcriptionally-activated Glycoprotein 1 Receptor, Tumor Necrosis Factor Receptor Superfamily
Ask
View Details MBS6254455-02 5x 0.1 mL
CD134 (CD134 Antigen, ACT35, ACT35 Antigen, Lymphoid Activation Antigen ACT35, OX40, OX40 Cell Surface Antigen, OX40 Homolog, OX40L Receptor, RP5-902P8.3, TAX Transcriptionally-activated Glycoprotein 1 Receptor, Tumor Necrosis Factor Receptor Superfamily
Ask
View Details 
